Horizon Pharma (NASDAQ:HZNP) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
This table compares Horizon Pharma and Clovis Oncology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Horizon Pharma and Clovis Oncology’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Horizon Pharma||$1.06 billion||3.01||-$410.52 million||$1.18||16.16|
|Clovis Oncology||$55.51 million||25.00||-$346.39 million||($5.12)||-5.15|
Clovis Oncology has lower revenue, but higher earnings than Horizon Pharma. Clovis Oncology is trading at a lower price-to-earnings ratio than Horizon Pharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Horizon Pharma has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
This is a summary of recent recommendations for Horizon Pharma and Clovis Oncology, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Horizon Pharma currently has a consensus target price of $22.18, suggesting a potential upside of 16.32%. Clovis Oncology has a consensus target price of $71.96, suggesting a potential upside of 172.98%. Given Clovis Oncology’s higher probable upside, analysts plainly believe Clovis Oncology is more favorable than Horizon Pharma.
Institutional and Insider Ownership
86.8% of Horizon Pharma shares are held by institutional investors. 3.9% of Horizon Pharma shares are held by insiders. Comparatively, 10.2% of Clovis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Horizon Pharma beats Clovis Oncology on 9 of the 14 factors compared between the two stocks.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.